| Naslov: | Case report: long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in prader willi syndrome - case series and literature review |
|---|
| Avtorji: | ID Koceva, Andrijana (Avtor)
ID Mlekuš, Katarina (Avtor)
ID Janež, Andrej (Avtor)
ID Herman, Rok (Avtor)
ID Ferjan, Simona (Avtor)
ID Jensterle Sever, Mojca (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (627,50 KB)
MD5: 3CD2D8FB0FD84E6AB059E0DD3F69655D
 URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.03 - Drugi znanstveni članki |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Introduction: Prader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging. Case series: We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery. Conclusion: Long-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions. |
|---|
| Ključne besede: | Prader-Willi syndrome, obesity, GLP-1 receptor agonist |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | 7 str. |
|---|
| Številčenje: | Vol. 15, [article no.] 1528457 |
|---|
| PID: | 20.500.12556/DiRROS-27506  |
|---|
| UDK: | 616.4 |
|---|
| ISSN pri članku: | 1664-2392 |
|---|
| DOI: | 10.3389/fendo.2024.1528457 |
|---|
| COBISS.SI-ID: | 223228675 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 14. 2. 2025;
|
|---|
| Datum objave v DiRROS: | 10.02.2026 |
|---|
| Število ogledov: | 523 |
|---|
| Število prenosov: | 180 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
